Stay updated on IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAn addition of Revision: v3.4.2 and a deletion of Revision: v3.4.1 were made in the page's revision history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; there are no changes to study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedAdded a Show glossary option and updated versioning/QC labels, including Last Update Submitted that Met QC Criteria and a new Revision: v3.4.0, with minor capitalization changes such as No FEAR Act Data.SummaryDifference0.2%

- Check42 days agoChange DetectedA minor revision tag v3.3.4 was added and v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded Locations section with Massachusetts and New York sites and updated the page revision to v3.3.3.SummaryDifference0.3%

- Check92 days agoChange DetectedUpdated the page to Revision: v3.3.2, replacing the previous v3.2.0. No core study information or documents were visibly changed.SummaryDifference0.1%

Stay in the know with updates to IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page.